
FOR GENERAL RELEASE TO THE PUBLIC
March 5, 2020

ANNOUNCEMENT REGARDING 2020 FINANCIAL YEAR GUIDANCE

This disclosure was made within the scope of public disclosure of future expectations, which is the 10th article of the Capital Markets Board's Communiqué No II-15.1.

Our company's expectations for 2020 are presented below:

- Consolidated revenue growth **18%**
- Adjusted EBITDA (excluding FX effect of other income/expenses from operating activities) growth **25%**
- The ratio of total maintenance capital expenditures to consolidated revenue is less than **2.0%**
- The ratio of total capital investment expenditure to consolidated revenue is less than **5.0%**
- Net debt / Adjusted EBITDA ratio below **2.0x**

Along with the decreasing market interest rates, 25-30% improvement is expected in interest cost compared to 2019.

In 2020, the Group has planned to add 2 hospitals with a total bed capacity of 300-400 in Istanbul and Gaziantep. These hospitals are planned to be opened with minimum investment expenditure and working capital requirement.

Disclosure to the public regarding the transactions and negotiations mentioned in this disclosure has been postponed by the Board of Directors until the conclusion of these studies within the scope of the decision to postpone disclosure of insider information contained in Article 6 of the CMB Communiqué II-15.1. The decision to postpone the material event was taken in order to prevent the process and activities to be adversely affected, to prevent the risks of misleading the investors about the legal rights and interests of our Company and to prevent the misconduct of the Company and not to violate the confidentiality obligations undertaken within this process. As the opening procedures of Gaziantep Hospital has been started on 05.03.2020, the reason for postponement has disappeared.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.

ENQUIRIES

Dr. Deniz Can Yücel

Head of Strategy and Investor Relations

T +90 212 227 5555 (Ext: 1148)

E deniz.yucel@mlpcare.com